July 5, 2017 | EphMRA, Patient-centricity, Richard Head, event, rare diseases
We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.
Director and EphMRA board member, Richard Head, Director, Jennifer Redfearn and Associate Director, An-hwa Lee represented us at the conference. On the Tuesday An-Hwa, who is a member of the EphMRA Learning and Development Committee, convened one of three of the pre-conference training workshops entitled ‘Skills Workshop: Qualitative’ which covered ethnography and projective techniques as qualitative methodologies.
Find out more https://www.researchpartnership.com/news/2017/06/ephmra-2017-round-up/
This content was provided by Inizio
Latest Content from Inizio
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding
Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,…
Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam
Brighton consultancy adds top honour to its award wins
Brighton-based independent healthcare specialist looks to add award to growing list of accolades
Top UK Healthcare Communications Consultancy Moves to Brighton
A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation…
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
